90 related articles for article (PubMed ID: 17484271)
1. Finding of no tumor (pT0) in patients undergoing radical retropubic prostatectomy for clinically localized prostate cancer.
Prayer-Galetti T; Gardiman M; Sacco E; Fracalanza S; Betto G; Pinto F
Anal Quant Cytol Histol; 2007 Apr; 29(2):79-86. PubMed ID: 17484271
[TBL] [Abstract][Full Text] [Related]
2. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
Noguchi M; Noda S; Nakashima O; Kojiro M
Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
[TBL] [Abstract][Full Text] [Related]
3. Follow-up of nondetectable prostate carcinoma (pT0) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy.
Köllermann J; Caprano J; Budde A; Weidenfeld H; Weidenfeld M; Hopfenmüller W; Helpap B
Urology; 2003 Sep; 62(3):476-80. PubMed ID: 12946750
[TBL] [Abstract][Full Text] [Related]
4. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S
Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
[TBL] [Abstract][Full Text] [Related]
6. The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer.
Joung JY; Kim JE; Kim SH; Seo HK; Chung J; Park WS; Hong EK; Lee KH
BMC Urol; 2015 Aug; 15():82. PubMed ID: 26269129
[TBL] [Abstract][Full Text] [Related]
7. [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].
Tabata K; Satoh T; Matsumoto K; Fujita T; Irie A; Iwamura M; Yanagisawa N; Matsuda D; Muramoto M; Kadowaki K; Suyama K; Shoji K; Koh H; Kawakami T; Okayasu I; Egawa S; Baba S
Nihon Hinyokika Gakkai Zasshi; 2006 Jul; 97(5):712-8. PubMed ID: 16898594
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
[TBL] [Abstract][Full Text] [Related]
9. [Neoadjuvant hormonal therapy versus surgery alone for radical prostatectomy in high-risk prostate cancer patients].
Kobayashi M; Saito Y; Komaru A; Fukasawa S; Suyama T; Akakura K; Ichikawa T; Ueda T
Hinyokika Kiyo; 2013 Jul; 59(7):411-8. PubMed ID: 23945319
[TBL] [Abstract][Full Text] [Related]
10. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
11. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
12. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of androgen deprivation therapy for localized prostate cancer: analysis of pT0 evaluated by radical prostatectomy specimen.
Kadono Y; Yaegashi H; Izumi K; Ueno S; Kitagawa Y; Mizokami A; Asahi H; Kobashi K; Koshida K; Namiki M
Anticancer Res; 2013 Mar; 33(3):1147-51. PubMed ID: 23482794
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of pT0 prostate cancer in patients undergoing radical prostatectomy.
Moreira DM; Gershman B; Rangel LJ; Boorjian SA; Thompson RH; Frank I; Tollefson MK; Gettman MT; Karnes RJ
BJU Int; 2016 Sep; 118(3):379-83. PubMed ID: 26305996
[TBL] [Abstract][Full Text] [Related]
15. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
16. Can pT0 stage of prostate cancer be predicted before radical prostatectomy?
Descazeaud A; Zerbib M; Flam T; Vieillefond A; Debré B; Peyromaure M
Eur Urol; 2006 Dec; 50(6):1248-52; discussion 1253. PubMed ID: 16828964
[TBL] [Abstract][Full Text] [Related]
17. Laparoscopic radical prostatectomy after neoadjuvant hormonal therapy: an apparently safe and effective procedure.
Brown JA; Garlitz C; Strup SE; Hubosky SG; Gomella L
J Laparoendosc Adv Surg Tech A; 2004 Dec; 14(6):335-8. PubMed ID: 15684777
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of stage pT0 after prolonged neoadjuvant endocrine therapy of prostate cancer: a matched-pair analysis.
Köllermann J; Hopfenmüller W; Caprano J; Budde A; Weidenfeld H; Weidenfeld M; Helpap B
Eur Urol; 2004 Jan; 45(1):42-5. PubMed ID: 14667514
[TBL] [Abstract][Full Text] [Related]
19. [Nondetectable prostate cancer in radical prostatectomy specimens].
Murányi M; Morshed AS; Benyó M; Tóth C; Flaskó T
Orv Hetil; 2012 Jan; 153(3):113-7. PubMed ID: 22236417
[TBL] [Abstract][Full Text] [Related]
20. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]